Zeleniuch-Jacquotte A - Search Results

1

Altered expression of p27 and Skp2 proteins in prostate cancer of African-American patients.

Drobnjak M, Melamed J, Taneja S, Melzer K, Wieczorek R, Levinson B, Zeleniuch-Jacquotte A, Polsky D, Ferrara J, Perez-Soler R, Cordon-Cardo C, Pagano M, Osman I. Drobnjak M, et al. Clin Cancer Res. 2003 Jul;9(7):2613-9. Clin Cancer Res. 2003. PMID: 12855638

2

Pharmacodynamics of topoisomerase I inhibition: Western blot determination of topoisomerase I and cleavable complex in patients with upper gastrointestinal malignancies treated with topotecan.

Liebes L, Potmesil M, Kim T, Pease D, Buckley M, Fry D, Cho J, Adler H, Dar K, Zeleniuch-Jacquotte A, Hochster H. Liebes L, et al. Clin Cancer Res. 1998 Mar;4(3):545-57. Clin Cancer Res. 1998. PMID: 9533521 Clinical Trial.

3

Expression of the cell cycle inhibitor p27KIP1 is a new prognostic marker associated with survival in epithelial ovarian tumors.

Newcomb EW, Sosnow M, Demopoulos RI, Zeleniuch-Jacquotte A, Sorich J, Speyer JL. Newcomb EW, et al. Am J Pathol. 1999 Jan;154(1):119-25. doi: 10.1016/S0002-9440(10)65258-3. Am J Pathol. 1999. PMID: 9916926 Free PMC article.

4

Response and determinants of sensitivity to paclitaxel in human non-small cell lung cancer tumors heterotransplanted in nude mice.

Perez-Soler R, Kemp B, Wu QP, Mao L, Gomez J, Zeleniuch-Jacquotte A, Yee H, Lee JS, Jagirdar J, Ling YH. Perez-Soler R, et al. Clin Cancer Res. 2000 Dec;6(12):4932-8. Clin Cancer Res. 2000. PMID: 11156254

5

Chemoprevention trials in men with prostate-specific antigen failure or at high risk for recurrence after radical prostatectomy: Application to efficacy assessment of soy protein.

Bosland MC, Kato I, Melamed J, Taneja S, Lepor H, Torre P, Walden P, Zeleniuch-Jacquotte A, Lumey LH. Bosland MC, et al. Urology. 2001 Apr;57(4 Suppl 1):202-4. doi: 10.1016/s0090-4295(00)00975-4. Urology. 2001. PMID: 11295628 Clinical Trial.

6

Double-blind trial of a polyvalent, shed-antigen, melanoma vaccine.

Bystryn JC, Zeleniuch-Jacquotte A, Oratz R, Shapiro RL, Harris MN, Roses DF. Bystryn JC, et al. Clin Cancer Res. 2001 Jul;7(7):1882-7. Clin Cancer Res. 2001. PMID: 11448900 Clinical Trial.

7

Expression of cell cycle regulators p57(KIP2), cyclin D1, and cyclin E in epithelial ovarian tumors and survival.

Rosenberg E, Demopoulos RI, Zeleniuch-Jacquotte A, Yee H, Sorich J, Speyer JL, Newcomb EW. Rosenberg E, et al. Hum Pathol. 2001 Aug;32(8):808-13. doi: 10.1053/hupa.2001.26462. Hum Pathol. 2001. PMID: 11521224

8

Chemoprevention strategies for prostate cancer.

Bosland MC, McCormick DL, Melamed J, Walden PD, Zeleniuch-Jacquotte A, Lumey LH. Bosland MC, et al. Eur J Cancer Prev. 2002 Aug;11 Suppl 2:S18-27. Eur J Cancer Prev. 2002. PMID: 12570331 Review.

9

Vaccine-induced CD8+ T-cell responses to MAGE-3 correlate with clinical outcome in patients with melanoma.

Reynolds SR, Zeleniuch-Jacquotte A, Shapiro RL, Roses DF, Harris MN, Johnston D, Bystryn JC. Reynolds SR, et al. Clin Cancer Res. 2003 Feb;9(2):657-62. Clin Cancer Res. 2003. PMID: 12576432

10

Changes in the presence of multiple markers of circulating melanoma cells correlate with clinical outcome in patients with melanoma.

Reynolds SR, Albrecht J, Shapiro RL, Roses DF, Harris MN, Conrad A, Zeleniuch-Jacquotte A, Bystryn JC. Reynolds SR, et al. Clin Cancer Res. 2003 Apr;9(4):1497-502. Clin Cancer Res. 2003. PMID: 12684425

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

310 results

Search Page

Filters